Video

Dr. Hoos on a Possible Successor Drug to Ipilimumab

Author(s):

Axel Hoos, MD, PhD

Dr. Axel Hoos Medical Lead in Immunology/Oncology at Bristol-Myers Squibb on a Possible Successor Drug to Ipilimumab

Axel Hoos, MD, PhD, the medical lead in Immunology/Oncology at Bristol-Myers Squibb discusses the multiple immunotherapy agents in development, including the most advanced anti-PD-1 agent MDX-1106 which has a similar mechanism of action to ipilimumab (Yervoy).

Related Videos
Dingwei Ye, MD, PhD
Areej El-Jawahri, MD, associate director, Cancer Outcomes Research and Education Program, director, Bone Marrow Transplant Survivorship Program, associate professor, medicine, Massachusetts General Hospital
Sandy Srinivas, MD
David Rimm, MD, PhD
Angeles A. Secord, MD, MHSc
Alexandra Drakaki, MD, PhD
Idoroenyi Amanam, MD
Sagar Lonial, MD, FACP
Leo I. Gordon, MD
Andrea Wolf, MD, MPH
Related Content
Gursel Aktan, MD, PhD
September 20th 2024

Pembrolizumab-Based Regimens Earn Positive CHMP Opinion in Endometrial and Cervical Cancers

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

The FDA has approved pembrolizumab (Keytruda) with pemetrexed and platinum chemotherapy as frontline treatment for patients with unresectable advanced or metastatic malignant pleural mesothelioma.
September 17th 2024

FDA Approves Pembrolizumab Plus Chemo for Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma

Jeffrey S. Weber, MD, PhD
November 6th 2023

FDA Approval Insights: Adjuvant Nivolumab in Completely Resected Stage IIB/C Melanoma

Thomas Powles, MBBS, MRCP, MD
September 15th 2024

Addition of Perioperative Durvalumab to Neoadjuvant Chemo Generates Survival Benefits in Cisplatin-Eligible MIBC

Dirk Schadendorf, MD
September 15th 2024

Early Switch Therapy to Atezolizumab After Vemurafenib/Cobimetinib Run-in Improves OS in BRAF V600–Positive Melanoma